6945 logo

AP Biosciences TPEX:6945 Stock Report

Last Price

NT$49.35

Market Cap

NT$4.2b

7D

-1.3%

1Y

3.5%

Updated

24 Dec, 2024

Data

Company Financials

6945 Stock Overview

A clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. More details

6945 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

AP Biosciences Inc Competitors

Price History & Performance

Summary of share price highs, lows and changes for AP Biosciences
Historical stock prices
Current Share PriceNT$49.35
52 Week HighNT$70.00
52 Week LowNT$44.40
Beta0
1 Month Change-0.40%
3 Month Change-11.08%
1 Year Change3.46%
3 Year Changen/a
5 Year Changen/a
Change since IPO-37.29%

Recent News & Updates

Recent updates

Shareholder Returns

6945TW BiotechsTW Market
7D-1.3%3.1%0.5%
1Y3.5%2.5%27.8%

Return vs Industry: 6945 exceeded the TW Biotechs industry which returned 1.6% over the past year.

Return vs Market: 6945 underperformed the TW Market which returned 28.7% over the past year.

Price Volatility

Is 6945's price volatile compared to industry and market?
6945 volatility
6945 Average Weekly Movement3.6%
Biotechs Industry Average Movement4.5%
Market Average Movement4.4%
10% most volatile stocks in TW Market7.8%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6945 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 6945's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201337Jeng-Horng Herwww.apbioinc.com

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. The company was founded in 2013 and is based in Taipei City, Taiwan.

AP Biosciences Inc Fundamentals Summary

How do AP Biosciences's earnings and revenue compare to its market cap?
6945 fundamental statistics
Market capNT$4.19b
Earnings (TTM)-NT$447.48m
Revenue (TTM)NT$32.25m

129.9x

P/S Ratio

-9.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6945 income statement (TTM)
RevenueNT$32.25m
Cost of RevenueNT$0
Gross ProfitNT$32.25m
Other ExpensesNT$479.74m
Earnings-NT$447.48m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-5.27
Gross Margin100.00%
Net Profit Margin-1,387.42%
Debt/Equity Ratio0%

How did 6945 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 16:12
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AP Biosciences Inc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution